103 related articles for article (PubMed ID: 23636305)
21. [Osteopontin as a potential biomarker of metastasis and recurrence for hepatocellular carcinoma].
Cui BK; Zhang CQ; Zhang Y; Yuan YF; Zhang YQ; Shi M; Chen MS; Li SP; Li JQ
Ai Zheng; 2006 Jul; 25(7):876-9. PubMed ID: 16831281
[TBL] [Abstract][Full Text] [Related]
22. Thirty-kilodalton Tat-interacting protein suppresses tumor metastasis by inhibition of osteopontin transcription in human hepatocellular carcinoma.
Zhao J; Lu B; Xu H; Tong X; Wu G; Zhang X; Liang A; Cong W; Dai J; Wang H; Wu M; Guo Y
Hepatology; 2008 Jul; 48(1):265-75. PubMed ID: 18537194
[TBL] [Abstract][Full Text] [Related]
23. Serum anti-osteopontin autoantibody as a novel diagnostic and prognostic biomarker in patients with hepatocellular carcinoma.
Ying X; Zhao Y; Wang JL; Zhou X; Zhao J; He CC; Guo XJ; Jin GH; Wang LJ; Zhu Q; Han SX
Oncol Rep; 2014 Oct; 32(4):1550-6. PubMed ID: 25109745
[TBL] [Abstract][Full Text] [Related]
24. Green tea component epigallocatechin-3-gallate decreases expression of osteopontin via a decrease in mRNA half-life in cell lines of metastatic hepatocellular carcinoma.
Zapf MA; Kothari AN; Weber CE; Arffa ML; Wai PY; Driver J; Gupta GN; Kuo PC; Mi Z
Surgery; 2015 Oct; 158(4):1039-47; discussion 1047-8. PubMed ID: 26189955
[TBL] [Abstract][Full Text] [Related]
25. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin.
Yu MC; Lee YS; Lin SE; Wu HY; Chen TC; Lee WC; Chen MF; Tsai CN
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S455-63. PubMed ID: 21822558
[TBL] [Abstract][Full Text] [Related]
26. Osteopontin in hepatocellular carcinoma: A possible biomarker for diagnosis and follow-up.
Cabiati M; Gaggini M; Cesare MM; Caselli C; De Simone P; Filipponi F; Basta G; Gastaldelli A; Del Ry S
Cytokine; 2017 Nov; 99():59-65. PubMed ID: 28711012
[TBL] [Abstract][Full Text] [Related]
27. Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner.
Phillips RJ; Helbig KJ; Van der Hoek KH; Seth D; Beard MR
World J Gastroenterol; 2012 Jul; 18(26):3389-99. PubMed ID: 22807608
[TBL] [Abstract][Full Text] [Related]
28. Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells.
Qiao N; Wang L; Wang T; Li H
Tumour Biol; 2016 Jun; 37(6):8169-79. PubMed ID: 26715277
[TBL] [Abstract][Full Text] [Related]
29. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma.
Sun BS; Dong QZ; Ye QH; Sun HJ; Jia HL; Zhu XQ; Liu DY; Chen J; Xue Q; Zhou HJ; Ren N; Qin LX
Hepatology; 2008 Dec; 48(6):1834-42. PubMed ID: 18972404
[TBL] [Abstract][Full Text] [Related]
30. Loss of E-cadherin mRNA and gain of osteopontin mRNA are useful markers for detecting early recurrence of HCV-related hepatocellular carcinoma.
Iso Y; Sawada T; Okada T; Kubota K
J Surg Oncol; 2005 Dec; 92(4):304-11. PubMed ID: 16299806
[TBL] [Abstract][Full Text] [Related]
31. CXCR7 expression correlates with tumor depth in cutaneous squamous cell carcinoma skin lesions and promotes tumor cell survival through ERK activation.
Hu SC; Yu HS; Yen FL; Chen GS; Lan CC
Exp Dermatol; 2014 Dec; 23(12):902-8. PubMed ID: 25256412
[TBL] [Abstract][Full Text] [Related]
32. [Relative analysis of OPN and its related signal molecules in hepatocellular carcinoma].
Zhang L; Li HY; Yin XL; Xu YP; Chen Y; Xie XY; Shen YF; Ye QH; Ren ZG
Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):48-51. PubMed ID: 21272459
[TBL] [Abstract][Full Text] [Related]
33. Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria.
Sieghart W; Wang X; Schmid K; Pinter M; König F; Bodingbauer M; Wrba F; Rasoul-Rockenschaub S; Peck-Radosavljevic M
J Hepatol; 2011 Jan; 54(1):89-97. PubMed ID: 20970216
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma.
Korita PV; Wakai T; Shirai Y; Matsuda Y; Sakata J; Cui X; Ajioka Y; Hatakeyama K
Hum Pathol; 2008 Dec; 39(12):1777-83. PubMed ID: 18701136
[TBL] [Abstract][Full Text] [Related]
35. Higher Matrix Stiffness Upregulates Osteopontin Expression in Hepatocellular Carcinoma Cells Mediated by Integrin β1/GSK3β/β-Catenin Signaling Pathway.
You Y; Zheng Q; Dong Y; Wang Y; Zhang L; Xue T; Xie X; Hu C; Wang Z; Chen R; Wang Y; Cui J; Ren Z
PLoS One; 2015; 10(8):e0134243. PubMed ID: 26280346
[TBL] [Abstract][Full Text] [Related]
36. RNA stability regulates differential expression of the metastasis protein, osteopontin, in hepatocellular cancer.
Emani S; Zhang J; Guo L; Guo H; Kuo PC
Surgery; 2008 Jun; 143(6):803-12. PubMed ID: 18549897
[TBL] [Abstract][Full Text] [Related]
37. Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer.
Iwakiri S; Mino N; Takahashi T; Sonobe M; Nagai S; Okubo K; Wada H; Date H; Miyahara R
Cancer; 2009 Jun; 115(11):2580-93. PubMed ID: 19309748
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of serum osteopontin in hepatocellular carcinoma patients treated with transarterial chemoembolization.
Kim SH; Chung YH; Yang SH; Kim JA; Jang MK; Kim SE; Lee D; Lee SH; Lee D; Kim KM; Lim YS; Lee HC; Lee YS; Suh DJ
Korean J Hepatol; 2009 Sep; 15(3):320-30. PubMed ID: 19783881
[TBL] [Abstract][Full Text] [Related]
39. The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection.
Chen D; Xing W; Hong J; Wang M; Huang Y; Zhu C; Yuan Y; Zeng W
Ann Surg Oncol; 2012 Oct; 19(11):3556-65. PubMed ID: 22588469
[TBL] [Abstract][Full Text] [Related]
40. Role of osteopontin and CD44s expression for patients with hepatocellular carcinoma undergoing liver transplantation or resection.
Beckebaum S; Chen X; Sotiropoulos GC; Radtke A; Daoudaki M; Baba HA; Wohlschlaeger J; Broelsch CE; Gerken G; Cicinnati VR
Transplant Proc; 2008 Nov; 40(9):3182-4. PubMed ID: 19010227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
